Long Qilai, Liu Li, Xia Yu, Bai Qi, Wang Jiajun, Xu Jiejie, Guo Jianming
Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China.
Tumour Biol. 2015 Sep;36(10):8007-14. doi: 10.1007/s13277-015-3525-9. Epub 2015 May 14.
B lymphoma Mo-MLV insertion region 1 homolog (Bmi-1) is a transcriptional repressor, which plays important roles in the development of cancers, but the function of Bmi-1 in kidney tumorigenesis and its prognostic values remain unclear. This study aims to investigate prognostic values of the intratumoral and peritumoral expression of Bmi-1 in patients with renal cell carcinoma. Expression of Bmi-1 was assessed by immunohistochemistry in specimens containing paired tumor and peritumoral renal tissue from 241 patients who had undergone curative nephrectomy at Zhongshan Hospital from 2005 to 2007. The association of Bmi-1 expression with clinical and pathological parameters and outcomes was investigated. Specific expression of Bmi-1 was found both in peritumoral and intratumoral tissues. High expression of Bmi-1 in peritumoral but not intratumoral is significantly associated with poor overall survival (OS) (P < 0.001) and relapse-free survival (RFS) (P = 0.003). Furthermore, Bmi-1 expression was identified as an independent prognostic factor for OS, and combination of peritumoral Bmi-1 and tumor node metastasis (TNM) stage had a better power to predict the patients' death and disease recurrence. High peritumoral Bmi-1 expression can serve as an independent prognostic biomarker and could be a novel therapeutic target for renal cell carcinoma (RCC).
B淋巴瘤莫洛尼鼠白血病病毒插入区1同源物(Bmi-1)是一种转录抑制因子,在癌症发展中发挥重要作用,但Bmi-1在肾肿瘤发生中的功能及其预后价值仍不清楚。本研究旨在探讨肾细胞癌患者肿瘤内和肿瘤周围Bmi-1表达的预后价值。通过免疫组织化学法评估了2005年至2007年在中山医院接受根治性肾切除术的241例患者的配对肿瘤和肿瘤周围肾组织标本中Bmi-1的表达。研究了Bmi-1表达与临床病理参数及预后的关系。在肿瘤周围和肿瘤内组织中均发现了Bmi-1的特异性表达。肿瘤周围而非肿瘤内Bmi-1的高表达与总生存期(OS)较差(P<0.001)和无复发生存期(RFS)较差(P=0.003)显著相关。此外,Bmi-1表达被确定为OS的独立预后因素,肿瘤周围Bmi-1与肿瘤淋巴结转移(TNM)分期相结合对预测患者死亡和疾病复发具有更好的能力。肿瘤周围Bmi-1高表达可作为独立的预后生物标志物,可能是肾细胞癌(RCC)的新型治疗靶点。